The test will enable early lung cancer detection, and will be a product without competitors.
Lab test automation company BioView Ltd. (TASE:BIOV) today announced that it had signed an agreement with the MD Anderson Cancer Research Center, which accords it the right of first refusal for use of lung cancer markers which the center developed.
BioView is engaged in automation of existing laboratory tests, (transferring the processing of a test from a lab technician to a machine,) and has also been developing its own test on the basis of new markers discovered by the center.
In its prospectus, the company had reported collaboration with MD Anderson on development of a lung cancer test. This agreement is a milestone on the way to commercialization of the test by BioView.
It is hoped that if and when the test is developed on the basis of these markers, it will enable discovery of lung cancer earlier than currently possible, and will operate in a niche without competition.
Published by Globes [online], Israel business news - www.globes.co.il - on March 4, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007